Efficacy of Mogamulizumab by Prior Systemic Therapy in Patients With Previously Treated Cutaneous T-Cell Lymphoma: Post Hoc Analysis From the Phase 3 MAVORIC Study

被引：0
|
作者：
Scarisbrick, J. [1 ]
Zinzani, P. L. [2 ]
Horwitz, S. [3 ]
Kim, Y. H. [4 ]
Moskowitz, A. J. [3 ]
Porcu, P. [5 ]
Leoni, M. [6 ]
Dwyer, K. [6 ]
Sun, W. [6 ]
Nikonova, E. [7 ]
Bagot, M. [8 ]
机构：
[1] Univ Hosp Birmingham, Birmingham, W Midlands, England
[2] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Stanford Univ, Stanford, CA 94305 USA
[5] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[6] Kyowa Kirin Pharmaceut Dev Inc, Princeton, NJ USA
[7] Kyowa Kirin Inc, Bedminster, NJ USA
[8] Univ Paris 07, Inserm U976, Hop St Louis, AP HP, Paris, France
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 185卷
关键词：
Cutaneous T-cell Lymphoma; Mogamulizumab; Mycosis Fungoides; Sezary syndrome;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BSH19-PO-0
引用
收藏
页码：94 / 94
页数：1
相关论文
共 43 条
  • [1] Time to Next Treatment in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL) Receiving Mogamulizumab or Vorinostat: A MAVORIC Post-Hoc Analysis
    Sokol, Lubomir
    Kim, Youn H.
    Ortiz-Romero, Pablo L.
    Pro, Barbara
    Scarisbrick, Julia
    Musiek, Amy
    Vermeer, Maarten
    Dummer, Reinhard
    Halwani, Ahmad
    Fierro, Maria Teresa
    Moriya, Junji
    Leoni, Mollie
    Bagot, Martine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S361 - S361
  • [2] Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial
    Horwitz, Steven
    Zinzani, Pier Luigi
    Bagot, Martine
    Kim, Youn H.
    Moskowitz, Alison J.
    Porcu, Pierluigi
    Dwyer, Karen
    Sun, Wei
    Herr, Fiona M.
    Scarisbrick, Julia
    LEUKEMIA & LYMPHOMA, 2021, 62 (13) : 3109 - 3118
  • [3] Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial
    Kim, Youn H.
    Bagot, Martine
    Pinter-Brown, Lauren
    Rook, Alain H.
    Porcu, Pierluigi
    Horwitz, Steven M.
    Whittaker, Sean
    Tokura, Yoshiki
    Vermeer, Maarten
    Zinzani, Pier Luigi
    Sokol, Lubomir
    Morris, Stephen
    Kim, Ellen J.
    Ortiz-Romero, Pablo L.
    Eradat, Herbert
    Scarisbrick, Julia
    Tsianakas, Athanasios
    Elmets, Craig
    Dalle, Stephane
    Fisher, David C.
    Halwani, Ahmad
    Poligone, Brian
    Greer, John
    Fierro, Maria Teresa
    Khot, Amit
    Moskowitz, Alison J.
    Musiek, Amy
    Shustov, Andrei
    Pro, Barbara
    Geskin, Larisa J.
    Dwyer, Karen
    Moriya, Junji
    Leoni, Mollie
    Humphrey, Jeffrey S.
    Hudgens, Stacie
    Grebennik, Dmitri O.
    Tobinai, Kensei
    Duvic, Madeleine
    LANCET ONCOLOGY, 2018, 19 (09) : 1192 - 1204
  • [4] Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma
    Duvic, Madeleine
    Pinter-Brown, Lauren C.
    Foss, Francine M.
    Sokol, Lubomir
    Jorgensen, Jeffrey L.
    Challagundla, Pramoda
    Dwyer, Karen M.
    Zhang, Xiaoping
    Kurman, Michael R.
    Ballerini, Rocco
    Liu, Li
    Kim, Youn H.
    BLOOD, 2015, 125 (12) : 1883 - 1889
  • [5] Quality of Life in Cutaneous T-cell Lymphoma Patients Treated with the Anti-CCR4 Monoclonal Antibody Mogamulizumab versus Vorinostat: Results from MAVORIC
    Huen, Auris
    Porcu, Pierluigi
    Hudgens, Stacie
    Quaglino, Pietro
    Cowan, Richard
    Floden, Lysbeth
    Tsianakas, Athanasios
    Leoni, Mollie
    Dale, Stephen
    Duvic, Madeline
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S289 - S289
  • [6] Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy
    Duvic, Madeleine
    Bates, Susan E.
    Piekarz, Richard
    Eisch, Robin
    Kim, Youn H.
    Lerner, Adam
    Robak, Tadeusz
    Samtsov, Alexey
    Becker, Juergen C.
    McCulloch, William
    Waksman, Joel
    Whittaker, Sean
    LEUKEMIA & LYMPHOMA, 2018, 59 (04) : 880 - 887
  • [7] Mogamulizumab Multimodality Therapy with Systemic Retinoids, Interferon, or Extracorporeal Photopheresis for Advanced Cutaneous T-Cell Lymphoma
    Weiner, David M.
    Rastogi, Supriya
    Lewis, Daniel J.
    Cohen, Leah
    Choi, Sara
    Vittorio, Carmela C.
    Haun, Paul L.
    Samimi, Sara S.
    Villasenor-Park, Jennifer
    Bhansali, Rahul S.
    Chong, Elise A.
    Landsburg, Daniel J.
    Nasta, Sunita D.
    Schuster, Stephen J.
    Svoboda, Jakub
    Kim, Ellen J.
    Rook, Alain H.
    Barta, Stefan K.
    DERMATOLOGIC THERAPY, 2023, 2023
  • [8] Mogamulizumab Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma (CTCL)
    Cowan, R.
    Scarisbrick, J.
    Dwyer, K.
    Leoni, M.
    Grebennik, D.
    Morris, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 77 - 78
  • [9] Understanding relative survival outcomes for patients with cutaneous T-cell lymphoma (CTCL) subtypes mycosis fungoides and Sezary syndrome treated with mogamulizumab or vorinostat: combining Australian real-world evidence and MAVORIC phase 3 trial data
    Remak, Edit
    Hawkins, Neil
    Jones, Trefor
    Otley, Marissa
    Twigger, Robert
    Prince, Miles
    EUROPEAN JOURNAL OF CANCER, 2021, 156 : S18 - S18
  • [10] Duration of Response in Cutaneous T-Cell Lymphoma Patients Treated With Denileukin Diftitox: Results From 3 Phase III Studies
    Duvic, Madeleine
    Geskin, Larisa
    Prince, H. Miles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2013, 13 (04) : 377 - 384
12345